Anavex Life Sciences Corp (AVXL)

[JB3729]

I simply quoted the Company. Ask them to define what you don't understand.

As for dosing -

This proof-of-concept study of 32 patients with mild-to-moderate Alzheimer’s disease (AD) demonstrated a favorable safety and tolerability/risk profile for ANAVEX 2-73, which activates the stressreducing and survival protein, the Sigma-1 receptor. Presented here is preliminary exploratory efficacy data through 31 weeks (26-week PART B including 5-week PART A) from the randomized (into different treatment regimes) open-label study with ANAVEX 2-73 oral daily dosing ranging from 10mg to 50mg (not optimized in PART B). Further analysis will be performed.